Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.
| Revenue (TTM) | $8.16B |
| Gross Profit (TTM) | $4.48B |
| EBITDA | $989.00M |
| Operating Margin | 3.49% |
| Return on Equity | 3.19% |
| Return on Assets | 2.08% |
| Revenue/Share (TTM) | $47.17 |
| Book Value | $28.27 |
| Price-to-Book | 3.09 |
| Price-to-Sales (TTM) | 1.89 |
| EV/Revenue | 2.409 |
| EV/EBITDA | 21.01 |
| Quarterly Earnings Growth (YoY) | 3.90% |
| Quarterly Revenue Growth (YoY) | -7.00% |
| Shares Outstanding | $170.22M |
| Float | $143.86M |
| % Insiders | 15.34% |
| % Institutions | 76.30% |
Volatility is currently expanding
Solventum beats Q3 earnings estimates despite an ERP-driven revenue decline, raises its 2026 EPS outlook and advances its portfolio transformation.
Reported sales decreased 7.0%; organic sales decreased 2.8%, reflecting the expected 630 basis point (bps) impact of prior quarter advance orders placed ahead of the planned ERP system cutover during the current quarter Expects full-year organic sales growth toward the high end of +2.5% to +3.0% range Increases full-year adjusted EPS guidance to $7.20 to $7.30 EAGAN, Minn., Nov. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2026.
SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
Besides Wall Street's top-and-bottom-line estimates for Solventum (SOLV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
Solventum's Q3 results are likely to face ERP-related order reversals and tariff pressures, while MedSurg, Dental and Acera growth may have supported underlying performance.
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Solventum gains FDA clearance to combine Restrata Matrix with V.A.C. Therapy, potentially expanding wound care applications and supporting long-term growth.
First-of-its-kind clearance combines two advanced wound care technologies into one path for active healing to help streamline care and improve patient outcomes Clearance pairs innovative synthetic electrospun fiber matrix technology with an industry-leading negative pressure wound therapy to optimize healing EAGAN, Minn., Oct. 19, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.
EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. financial markets close.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SOLV and any ticker you trade — then tracks every position and per-strategy win rate.
